127 withdrawn. 127 Phase 3, 30 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 127 | Withdrawn 127 |
| Phase 2 | 30 | Withdrawn 30 |
Follow Digestive System Diseases: new trials by email Literature Review of Digestive System Diseases trials Research Report on Digestive System Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD) Linaprazan glurate - High dose, Linaprazan glurate - Low dose, Lansoprazole - Marketed approved dose - GERD (Gastroesophageal Reflux Disease) | Phase 3 | Withdrawn | Cinclus Pharma Holding AB | 2026-03-01 | 2026-05-28 | |
| Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma) Recombinant Hepatitis B new Bulk vaccine, DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine, Recombinant Hepatitis B vaccine (Registered BioFarma) - Diphtheria Vaccine Adverse Reaction, Tetanus Vaccine Adverse Reaction | Phase 3 | Withdrawn | PT Bio Farma | 2025-12-01 | 2025-06-05 | |
| A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis Mesalamine, Placebo - Ulcerative Colitis (UC) | Phase 3 | Withdrawn | AbbVie | 2025-09-15 | 2025-08-12 | |
| COPPER: A Trial Evaluating Copper-based Products for Incontinence-associated Dermatitis Diaper with a copper-based product + usual care, Barrier product with common diaper - Incontinence-associated Dermatitis | Phase 2 / Phase 3 | Withdrawn | Hospital Israelita Albert Einstein | 2025-09-01 | 2026-01-12 | |
| Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis Rifaximin 550 MG Oral Tablet [XIFAXAN], Placebo - Cystic Fibrosis, Abdominal Pain | Phase 2 / Phase 3 | Withdrawn | Wake Forest University Health Sciences | 2025-07-01 | 2025-06-27 | |
| A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis Denifanstat, Placebo - MASH, NASH | Phase 3 | Withdrawn | Sagimet Biosciences Inc. | 2025-03-01 | 2025-05-15 | |
| A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH denifanstat, Placebo - MASLD, MASH | Phase 3 | Withdrawn | Sagimet Biosciences Inc. | 2025-03-01 | 2025-05-15 | |
| Immunoscore As Decision Guidance for Adjuvant Chemotherapy in Colon Cancer Capecitabine, Oxaliplatin, Fluorouracil - Colon Cancer Stage III | Phase 3 | Withdrawn | Johannes Laengle, MD, PhD | 2024-12-01 | 2024-09-20 | |
| A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects With Primary Sclerosing Cholangitis. aldafermin, Placebo - Primary Sclerosing Cholangitis | Phase 2 / Phase 3 | Withdrawn | NGM Biopharmaceuticals, Inc | 2024-10-21 | 2025-05-07 | |
| SAVES-IBD: Safety & Efficacy of Aspirin vs. Standard of Care for VTE Prophylaxis After IBD Surgery Aspirin 81Mg Ec Tab, Standard of Care - Crohn Disease, Ulcerative Colitis | Phase 3 | Withdrawn | Stefan Holubar MD MS FACS, FASCRS | 2024-06-01 | 2024-04-18 | |
| Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer Nimotuzumab injection, Placebo, Trifluridine/tipiracil - Refractory Metastatic Colorectal Cancer | Phase 3 | Withdrawn | Biotech Pharmaceutical Co., Ltd. | 2024-04-03 | 2026-10-05 | |
| Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma Sitravatinib, Tislelizumab, sitravatinib-matching placebo - Hepatocellular Carcinoma | Phase 3 | Withdrawn | BeiGene | 2023-06-30 | 2023-06-07 | |
| BSEP Function Rescue During Childhood Inhereditary Cholestatic Diseases 4-Phenylbutyrate - Hereditary Diseases, Cholestasis, Intrahepatic | Phase 2 / Phase 3 | Withdrawn | Children's Hospital of Fudan University | 2023-02-08 | 2023-02-09 | |
| A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC HLX10, HLX04, Sorafenib - Hepatocellular Carcinoma (HCC) | Phase 3 | Withdrawn | Shanghai Henlius Biotech | 2022-11-15 | 2022-05-05 | |
| Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients ABX464, Placebo - Crohn Disease | Phase 2 / Phase 3 | Withdrawn | Abivax S.A. | 2022-09-19 | 2024-07-31 | |
| Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer Metabolic treatment - Cancer, Overall Survival | Phase 3 | Withdrawn | Health Clinics Limited | 2022-05-23 | 2022-07-18 | |
| A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis AK002, Placebo - Eosinophilic Gastritis, Eosinophilic Duodenitis | Phase 3 | Withdrawn | Allakos Inc. | 2021-12-01 | 2023-03-03 | |
| MNK-6105 for Patients With Cirrhosis and High Ammonia Levels Affecting Brain Function MNK-6105, Placebo, Standard of Care - Hepatic Encephalopathy | Phase 3 | Withdrawn | Mallinckrodt | 2021-11-01 | 2021-09-22 | |
| Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility Rifaximin - Cirrhosis, Liver, Minimal Hepatic Encephalopathy | Phase 3 | Withdrawn | MetroHealth Medical Center | 2021-09-15 | 2025-12-24 | |
| A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis OligoG Dry powder for inhalation - Cystic Fibrosis | Phase 2 / Phase 3 | Withdrawn | AlgiPharma AS | 2021-09-01 | 2022-06-30 |
Showing 20 of 127. Sign in to see all of them.
Carcinoma, Hepatocellular (15) · Colorectal Neoplasms (10) · Hepatitis C, Chronic (10) · Crohn Disease (9) · Hepatitis C (9) · Colitis, Ulcerative (6) · Cystic Fibrosis (6) · Gastroesophageal Reflux (6) · Colonic Neoplasms (5) · Pancreatic Neoplasms (5) · Stomach Neoplasms (5) · Fibrosis (4) · Inflammatory Bowel Diseases (4) · Irritable Bowel Syndrome (4) · Non-alcoholic Fatty Liver Disease (4)
Gastrointestinal Diseases (64) · Liver Diseases (48) · Digestive System Neoplasms (45) · Neoplasms (45) · Neoplasms by Site (45) · Intestinal Diseases (39) · Pathological Conditions, Signs and Symptoms (35) · Pathologic Processes (27) · Colonic Diseases (24) · Infections (24) · Hepatitis (23) · Blood-Borne Infections (22) · Communicable Diseases (22) · Gastrointestinal Neoplasms (22)
Ribavirin (12) · Fluorouracil (9) · Oxaliplatin (8) · Cisplatin (6) · peginterferon alfa-2b (6) · Capecitabine (5) · Gemcitabine (5) · Leucovorin (5) · peginterferon alfa-2a (5) · Rifaximin (4) · Certolizumab Pegol (3) · Folfox protocol (3) · N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide (3) · lenvatinib (3) · Adalimumab (2)
Merck Sharp & Dohme LLC (6) · Guangxi Medical University (4) · Seoul National University Hospital (3) · AbbVie (2) · Bausch Health Americas, Inc. (2) · Boehringer Ingelheim (2) · Bristol-Myers Squibb (2) · Eurofarma Laboratorios S.A. (2) · Hoffmann-La Roche (2) · Marathon Pharmaceuticals, LLC (2) · Medical College of Wisconsin (2) · NYU Langone Health (2) · Sagimet Biosciences Inc. (2) · Samsung Medical Center (2) · Sun Yat-sen University (2)
United States (24) · China (15) · South Korea (11) · Canada (6) · Israel (4) · Italy (4) · Egypt (3) · Germany (3) · India (3) · Spain (3) · Taiwan (3) · United Kingdom (3) · Australia (2) · Austria (2) · Belgium (2)
Lequn Li, PhD (3) · Ming Shi, MD (3) · John Lahey (2) · Albert Koong (1) · Albert Koong, MD, PhD (1) · Alfred M. Cohen, M.D. (1) · Amit Assa, MD (1) · Andrea Kelly, MD (1) · Arnaud Fontanet, MD, PhD (1) · Baha Moshiree, MD (1)
PMID 15756212, PMID 19302262, PMID 20082715, PMID 20675008, PMID 20849805, PMID 21058409, PMID 21157444, PMID 23980077, PMID 25932262, PMID 26644276, PMID 32716060, PMID 33772456, PMID 40404984
2018 (3), 2014 (2), 2017 (2), 2019 (2), 2015 (1), 2025 (1), P30CA042014 (1), R01CA080852 (1)